Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Idorsia Ltd.

http://www.idorsia.com

Latest From Idorsia Ltd.

Seven Potential Blockbuster Approvals To Look Out For In 2023

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.

Approvals Companies

Idorsia’s Quviviq Needs To Rise And Shine After Slow Launch

The company’s Quviviq launch has fallen short of early expectations, but Idorsia believes a patient approach will pay off for the blockbuster-tipped insomnia treatment.

Commercial Companies

Sangamo Can Take Lead In Fabry Gene Therapy

Avrobio dropping out of the race means Sangamo can take advantage but its gene therapy must show long-term efficacy in patients not receiving enzyme replacement therapy.

Rare Diseases Research & Development

Keeping Track: Idorsia’s Quviviq Is FDA’s First Novel Approval Of 2022; AbbVie’s Rinvoq Gains Eczema Claim

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals
See All

Company Information

UsernamePublicRestriction

Register